` SIBN (SI-BONE Inc) vs S&P 500 Comparison - Alpha Spread

SIBN
vs
S&P 500

Over the past 12 months, SIBN has significantly outperformed S&P 500, delivering a return of 40% compared to the S&P 500's 10% growth.

Stocks Performance
SIBN vs S&P 500

Loading
SIBN
S&P 500
Add Stock

Performance Gap
SIBN vs S&P 500

Loading
SIBN
S&P 500
Difference

Performance By Year
SIBN vs S&P 500

Loading
SIBN
S&P 500
Add Stock

Competitors Performance
SI-BONE Inc vs Peers

SI-BONE Inc
Glance View

Economic Moat
None
Market Cap
837.3m USD
Industry
Health Care

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.

SIBN Intrinsic Value
20.92 USD
Undervaluation 6%
Intrinsic Value
Price
Back to Top